Traws Pharma Soars on Hantavirus Push After Cruise Fatalities
Traws Pharma shares surged over 21% after the biotech said it would advance hantavirus drug candidates following a fatal cruise ship outbreak. The company has no approved treatments and recently raised $10 million.
Markets
